Advertisement
With the fast moving, ever-changing landscape of healthcare today, the mission of AJMC TV is to inform payers, clinical decision makers, and policy makers through brief video interviews providing the most recent and important information.
Lee Newcomer, MD, MHA, of Oncology, Genetics and Women's Health for UnitedHealthcare, says the National Comprehensive Cancer Network is transforming genetic testing by utilizing a tool called the NCCN Biomarkers Compendium, which encourages evidence-based decision-making.
AJMC INTERVIEWS
Edmund J. Pezalla, MD, MPH, national medical director, Aetna Pharmacy Management, says that Aetna recognizes the implications of the obesity epidemic and how it contributes to a variety of other medical problems such as diabetes and hypertension.
AJMC INTERVIEWS
Christine Strahl, PharmD, MBA, BCPS, specialty pharmacy program manager, HealthPartners, says there are several new distribution channels in specialty pharmacy.
During this segment, the panelists review the use of personalized medicine in castration-resistant prostate cancer.
Stephane A. Regnier, PhD, MBA
Bruce Feinberg, DO; Scott Milligan, PhD; Tim Olson, MBA; Winston Wong, PharmD; Daniel Winn, MD; Ram Trehan, MD; and Jeffrey Scott, MD
Sabina Ohri Gandhi, PhD; and Lindsay Sabik, PhD
Current Issue | Archives
Effective and Efficient Diagnosis of Parkinsonism: The Role of Dopamine Transporter SPECT Imaging With Ioflupane I-123 Injection (DaTscan™)
Effective and Efficient Diagnosis of Parkinsonism: The Role of Dopamine Transporter SPECT Imaging With Ioflupane I-123 Injection (DaTscan™)
Volume: 20
Number: 5 Suppl
Number: 5 Suppl
Sara C. Erickson, PharmD; Wenyi Qiu, MS; Crystal R. Maas-Patel, PharmD; Sharon M. Wang, PharmD, MS; and Bimal V. Patel, PharmD, MS
Myrl Weinberg, FASAE, CAE
Catherine I. Starner, PharmD, BCPS; R. Scott McClelland, PharmD; Yang Qiu, MS; Richard A. Zabinski, PharmD; Nancy Cotter, PharmD; and Patrick P. Gleason, PharmD, BCPS, FCCP
Mary K. Caffrey
Andrew D. Smith
Jennifer L. Redmond, DrPH
Mary K. Caffrey
Stanton R. Mehr
Leah Schmidt, SNS
Advertisement
Wednesday, April 23rd, 2014
HCV Drug Sets Record Sales Katie Sullivan, MA
Initial sales of Sovaldi (sofosbuvir), Gilead’s new drug for the treatment of hepatitis C virus infection (HCV), set a sales record in its first quarter on the market in the United States. In fact, Sovalidi outpaced the sales of any other drug in its class, netting $2.1 billion in revenue—or approximately $25 million per day.
Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.
Newsroom
Advertisement
Advertisement
About Us | Contact Us | Terms & Conditions | Privacy Policy | Press Room | Copyright HCPLive 2006-2014 | Intellisphere, LLC. All Rights Reserved.
Partner Websites: Pharmacy Times | Targeted Therapies | PainLive | HCPLive | ONCLive | Specialty Pharmacy Times